Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen sa-nv - smectite dioctaed 3000 mg; aluminium hydroxide-magnesium carbonate coprecipitate 125 mg - powder for oral suspension - smectite dioctaed 3000 mg; aluminium hydroxide-magnesium carbonate 125 mg - diosmectite

Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour ipsen pharma - smectite aluminium hydroxide-magnesium carbonate - powder for oral suspension - grams

Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour schwabe - smectite aluminium hydroxide magnesium hydroxide - oral suspension - 15.8 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour ipsen pharma - smectite aluminium hydroxide-magnesium carbonate - powder for oral suspension

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - diosmectite -

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ursodeoxycholic acid 250mg;  ;   - capsule - 250 mg - active: ursodeoxycholic acid 250mg     excipient: capsugel white op colloidal silicon dioxide magnesium stearate maize starch pregelatinised maize starch - ursosan is indicated in the treatment of chronic cholestatic liver diseases, including primary biliary cirrhosis (pbc) and primary sclerosing cholangitis (psc). in primary biliary cirrhosis ursodeoxycholic acid improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, i.e. serum bilirubin less that 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.

Israel - English - Ministry of Health

rafa laboratories ltd - ursodeoxycholic acid - film coated tablets - ursodeoxycholic acid 500 mg - ursodeoxycholic acid - ursodeoxycholic acid - for the symptomatic treatment of primary biliary cirrhosis (pbc), in patients without decompensated hepatic cirrhosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; maize starch; silicon dioxide; gelatin; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; polysorbate 80; crospovidone; purified talc; macrogol 6000; magnesium stearate; povidone; colloidal anhydrous silica; hypromellose - the treatment of chronic cholestatic liver diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases